Hepatocellular carcinoma-epidemiological trends and risk factors

Digestive Diseases

Volumn 27, Issue 2, 2009, Pages 80-92

  Schütte, Kerstin ^a   Bornschein, Jan ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Autoimmune hepatitis (AIH) related HCC; HCC epidemiological trends; HCC risk factors; Hepatitis B associated HCC; Hepatitis C associated HCC; Hepatocarcinogenesis; Viral hepatitis

Indexed keywords

AFLATOXIN B1; ALCOHOL; ALPHA 1 ANTITRYPSIN; HEPATITIS B VACCINE; INTERFERON; IRON; TOXIC SUBSTANCE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOIMMUNE HEPATITIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; COFFEE; DIABETES MELLITUS; DIET; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; IRON OVERLOAD; KNOWLEDGE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS HEPATITIS;

AFLATOXINS; ALCOHOL DRINKING; ALPHA 1-ANTITRYPSIN DEFICIENCY; CARCINOMA, HEPATOCELLULAR; COFFEE; DIABETES COMPLICATIONS; DIET; FATTY LIVER; FEMALE; HEMOCHROMATOSIS; HEPATITIS; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; RISK FACTORS;

EID: 67650938576     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218339     Document Type: Review

References (139)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni J: International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-296.
4. Rocken C, Carl-McGrath S: Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001;19:269-278.
5. Moller H, Mellemgaard A, Lindvig K, Ol- sen JH: Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344-350.
6. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336: 1855-1859.
7. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS: The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-782.
8. Wong JB, McQuillan GM, McHutchison JG,Poynard T: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:15621569.
9. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62(suppl 1):8-17.
10. Fattovich G, Giustina G, Schalm SW, Hadzi-yannis S, Sanchez-Tapias J, Almasio P, Chris-tensen E, Krogsgaard K, Degos F, De MouraMC, Solinas A, Noventa F, Realdi G, Alberti A, Quero C, Savvas S, Mas A, Craxi A, Olsen JF: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995;21:77-82.
11. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
12. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD: A follow-up study of urinary markers of afla- toxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 310.
13. 1. Proc NatlAcad Sci USA 1995; 92: 2384-2387.
14. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu V, Liu G, Wu Y, Zhu Y: Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999;30: 379-383.
15. Rudolph KL, Chang S, Millard M, Schreiber- Agus N, DePinho RA: Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-1258.
16. Kao JH, Chen DS: Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 2005;25:696-703.
17. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
18. Evert M, Dombrowski F: Hepatocellular carcinoma in the noncirrhotic liver. Pathologe 2008;29:4752.
19. Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK: Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a casecontrol study of 213 hepatocellular car cinoma patients from India. J Gastroenterol Hepatol 2007; 22:11041111.
20. Schuppan D, Afdhal NH: Liver cirrhosis.Lancet 2008;371:838851
21. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5S16.
22. Bosch F, Ribes J: The epidemiology of primary liver cancer: global epidemiology; in Tabor E (ed): Viruses and Liver Cancer, ed 1. Amsterdam, Elsevier, 2002, pp 116.
23. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Longterm outcome of hepatitis B e antigenpositive patients with compensated cirrhosis treated with interfer ona. Hepatology 1997;26:13381342.24 Liu CJ, Chen BF, Chen PJ, Lai MY, Huang
24. WL, Kao JH, Chen DS: Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193:12581265.
25. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA2006; 295: 6573.
26. Yuen MF, Tanaka Y, Fong DYT, Fung J,Wong DKH, Yuen JCH, But DYK, Chan AOO, Wong BCY, Mizokami M, Lai CL: Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:8088.
27. Yang HI, Lu SN, Liaw YF, You SL, Sun CA,Wang LY, Hsiao CK, Chen PJ, Chen DS,Chen CJ: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168174.
28. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a metaanalysis. J Viral Hepat 2009; 16: 265271.
29. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF: Interferon therapy in HBeAgpositive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:4552.
30. Liaw YF: Natural history of chronic hepatitisB virus infection and longterm outcome under treatment. Liver Int 2009;29:100107.
31. Liu CJ, Kao JH, Chen DS: Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:10971107.
32. Kao JH: Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervi rology 2003; 46:400407.
33. Chan HLY, Hui AY, Wong ML, Tse AML,Hung LCT, Wong VWS, Sung JJY: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 14941498.
34. Chan HLY, Tse CH, Mo F, Koh J, Wong VWS, Wong GLH, Chan SL, Yeo W, Sung JJY, Mok TSK: High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. JClin Oncol 2008;26:177182.
35. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL,Su J, Wang LY, Lu SN, You SL, Chen DS, LiawYF, Chen CJ: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:11341143.
36. Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DYK, Fong DYT, Fung J, Wong DKH, Yuen JCH, Mizokami M, Lai CL: Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57: 98102.
37. Kao JH: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643650.
38. Gomaa AI, Khan SA, Toledano MB, Waked I, TaylorRobinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14:43004308.
39. Fattovich G, Giustina G, Christensen E, Pan talena M, Zagni I, Realdi G, Schalm SW: Influence of hepatitis delta virus infection on morbidity and mortality in compensatedcirrhosis type B. Gut 2000; 46:420426.
40. Tamura I, Kurimura O, Koda T, Ichimura H,Katayama S, Kurimura T, Inaba Y: Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. J Gas troenterol Hepatol 1993; 8: 433436.
41. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155: 323331.
42. ElSerag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74S83.
43. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Kobayashi M, Nakamura I, Murashima N, Kumada H,Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a longterm observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:11241130.
44. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solfo rosi L, Morabito A, Ideo G, Podda M: Long term beneficial effects in sustained respond ers to interferona therapy for chronic hepatitis C. J Hepatol 2001;34:748755.
45. Goodgame B, Shaheen NJ, Galanko J, ElSe rag HB: The risk of endstage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol 2003;98:2535-2542.
46. Seeff LB: The history of the 'natural history'of hepatitis C (19682009). Liver Int 2009;29:8999.
47. Seeff LB: Natural history of hepatitis C. Hepatology 1997;26:21S28S.
48. Leone N, Rizzetto M: Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005;51:3146.
49. Amarapurkar D: Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 2000;15:E105E110.
50. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825832.
51. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kal dor JM: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepa tology 2001;34:809816.
52. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT,Lindsay KL, Lee WM, Bonkovsky HL, Diens tag JL, Ghany MG, Morishima C, Goodman ZD: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis Cre lated advanced liver disease. Gastroenterol ogy 2009;136:138148.
53. Yoshida H, Shiratori Y, Moriyama M, Ara kawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131:174181.
54. Liang TJ, Heller T: Pathogenesis of hepatitis Cassociated hepatocellular carcinoma. Gastroenterology 2004;127:S62S71.
55. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001;345:4152.
56. Sung VM, Shimodaira S, Doughty AL, Pic chio GR, Can H, Yen TS, Lindsay KL, Levine AM, Lai MM: Establishment of Bcell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003;77:21342146.
57. Donato F, Boffetta P, Puoti M: A metaanalysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347354.
58. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnu L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, An dreone P, Stanzione M, Mazzella G, Saracco G, Del Poggio P, Bruno S: Lack of correlation between serum antiHB core detectability and hepatocellular carcinoma in patients with HCVrelated cirrhosis. Am J Gastroen terol 2008;103:19661972.
59. Morgan TR, Mandayam S, Jamal MM: Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127:S87S96.
60. Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesis with special mphasis on alcohol and oxidative stress.Biol Chem 2006; 387: 349360.
61. Prior P: Longterm cancer risk in alcoholism. Alcohol Alcohol 1988;23:163171.
62. Becker U, Deis A, Sorensen TIA, GranbaskM, BorchJohnsen K, Muller CF, Schnohr P,Jensen G: Prediction of risk of liver disease y alcohol intake, sex, and age: a prospective opulation study. Hepatology 1996;23:10251029.
63. Inoue H, Seitz HK: Viruses and alcohol in he pathogenesis of primary hepatic carcinoma. Eur J Cancer Prev 2001; 10:107110.
64. Homann N, Stickel F, Konig IR, Jacobs A,Junghanns K, Benesova M, Schuppan D,Himsel S, ZuberJerger I, Hellerbrand C,Ludwig D, Caselmann WH, Seitz HK: Alcohol dehydrogenase 1C*1 allele is a geneticmarker for alcoholassociated cancer in eavy drinkers. Int J Cancer 2006; 118:1998-2002.
65. Seitz HK, Osswald BR: Effect of ethanol on procarcinogen activation; in Watson RR (ed): Alcohol and the Gastrointestinal Tract. Boca Raton, CRC Press, 1992, pp 5572.
66. Chung BH, Mitchell SH, Zhang JS, Young CYF: Effects of docosahexaenoic acid and eicosapentaenoic acid on androgenmedi ated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 2001;22:12011206.
67. Chung J, Liu C, Smith DE, Seitz HK, Russell RM, Wang XD: Restoration of retinoic acid concentration suppresses ethanolenhanced cJun expression and hepatocyte proliferation in rat liver. Carcinogenesis 2001; 22:12131219.
68. Wang XD, Liu C, Chung J, Stickel F, Seitz HK, Russell RM: Chronic alcohol intake reduces retinoic acid concentration and enhances AP1 (cJun and cFos) expression in rat liver. Hepatology 1998;28:744750.
69. Liu C, Russell RM, Seitz HK, Wang XD: Eth anol enhances retinoic acid metabolism into polar metabolites in rat liver via induction of cytochrome P4502E1. Gastroenterology 2001;120:179189.
70. Ohnishi K, Iida S, Iwama S: The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 1982; 49: 672677.
71. Stickel F, Schuppan D, Hahn EG, Seitz HK:Cocarcinogenic effects of alcohol in hepato carcinogenesis. Gut 2002;51:132139.
72. Craddock VM: Metabolism of ethanol and higher alcohols present in alcoholic drinks and their corresponding aldehydes in sub cellular components of rat esophageal mu cosa, and relevance for esophageal cancer in men; in Palmer TN (ed): Alcoholism: a Molecular Perspective. New York, Plenum Press, 1991, pp 297301.
73. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO: Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85: 498502.
74. Donato F, Gelatti U, Limina RM, FattovichG: Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006; 25: 37563770.
75. Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G, Gelatti U, Bucella E, To masi E, Portolani N, Bonetti M, Bettini L, Pelizzari G, Salmi A, Savio A, Garatti M, Callea F: Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000;9:213216.
76. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:13491354.
77. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterol ogy 2002;123:134140.
78. Takamatsu S, Noguchi N, Kudoh A, Naka mura N, Kawamura T, Teramoto K, Igari T,Arii S: Influence of risk factors for metabolic syndrome and nonalcoholic fatty liver disease on the progression and prognosis of he patocellular carcinoma. Hepatogastroenterology 2008; 55: 609614.
79. Regimbeau JM, Colombat M, Mognol P, Du rand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J: Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69S73.
80. NeuschwanderTetri BA: Nonalcoholic ste atohepatitis and the metabolic syndrome.Am J Med Sci 2005; 330: 326335.
81. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC: Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007; 17:14571463.
82. Gholam PM, Flancbaum L, MacHan JT,Charney DA, Kotler DP: Nonalcoholic fattyliver disease in severely obese subjects. Am J Gastroenterol 2007;102:399408.
83. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Ke chagias S: Longterm followup of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865873.
84. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH: Metabolic disturbances in nonalcoholic fatty liver disease. Clin Sci (Lond) 2009; 116: 539564.
85. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ: Does nonalcoholic fatty liver disease predispose patients to he patocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:17611766.
86. Caldwell SH, Crespo DM, Kang HS, Al Osaimi AMS: Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127:S97S103.
87. Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, Kurokawa F, Maeya ma S, Okita K: Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 2004; 39:391396.
88. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851859.
89. Davila JA, Morgan RO, Shaib Y, McGlynn KA, ElSerag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a populationbased casecontrol study. Gut 2005; 54:533539.
90. ElSerag HB, Richardson PA, Everhart JE: The role of diabetes in hepatocellular carcinoma: a casecontrol study among United States Veterans. Am J Gastroenterol 2001; 96:24622467.
91. Donadon V, Balbi M, Casarin P, Vario A, Al berti A: Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gas troenterol 2008; 14: 56955700.
92. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R: The impact of obesity and diabetes mellitus on the risk of he patocellular carcinoma. Ann Oncol 2009; 20:353357.
93. ElSerag HB, Hampel H, Javadi F: The association between diabetes and hepatocellular carcinoma: a systematic review of epidemio logic evidence. Clin Gastroenterol Hepatol2006;4:369380.
94. Torisu Y, Ikeda K, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Kawamura T, Yatsuji H, Suzuki F, Suzuki Y, Arase Y, Kumada H: Diabetes mellitus increases the risk of hepato carcinogenesis in patients with alcoholic cirrhosis: a preliminary report. Hepatol Res2007;37: 517523.
95. N'Kontchou G, Paries J, Htar MTT, Ganne Carrie N, Costentin L, GrandoLemaire V, Trinchet J, Beaugrand M: Risk factors for hepatocellular carcinoma in patients with alcoholic or viral c cirrhosis. Clin Gastro enterol Hepatol 2006; 4: 10621068.
96. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ: Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a followup study in Taiwan. Gastroenterology 2008; 135: 111121.
97. Calle EE, Rodriguez C, WalkerThurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:16251638.
98. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M: Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008; 6:459464.
99. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS: Alcohol, tobacco and obesity are synergistic risk factors for hepa tocellular carcinoma. J Hepatol 2005; 42: 218224.
100. Nair S, Mason A, Eason J, Loss G, Perrillo RP: Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?Hepatology 2002;36:150155.
101. Adams LA, Sanderson S, Lindor KD, An gulo P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132138.
102. Teufel A, Galle PR, Kanzler S: Update on autoimmune hepatitis. World J Gastroen terol 2009;15:10351041.
103. Watanabe TF, Soga KF, Hirono HF, Hasega wa KF, Shibasaki KF, Kawai HF, Aoyagi Y: Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroen terol 2009;15:231239.
104. Yeoman AD, AlChalabi T, Karani JB, Qua glia A, Devlin J, MieliVergani G, Bomford A, O'Grady JG, Harrison PM, Heneghan MA: Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for followup and screening. Hepatology 2008;48:863870.
105. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, Bergquist A,SandbergGertzen H, Hultcrantz R, Sang felt P, Weiland O, Danielsson A: Hepatic and extrahepatic malignancies in autoimmune hepatitis. A longterm followup in 473 Swedish patients. J Hepatol 2009; 50: 388393.
106. MontanoLoza AJ, Carpenter HA, Czaja AJ: Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis.Am J Gastroenterol 2008; 103:19441951.
107. Kew MC: Hepatic iron overload and hepatocellular carcinoma. Cancer Lett 2008,Dec 9 (Epub ahead of print).108 Kowdley KV: Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterolo gy 2004;127:S79S86.
108. Asare GA, Paterson AC, Kew MC, Khan S,Mossanda KS: Ironfree neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol 2006; 208: 8290.
109. Asare GA, Bronz M, Naidoo V, Kew MC: Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis. Toxicology 2008; 254: 1118.
110. Blanc JF, Ledinghen VD, Bernard PH, Ver neuil HD, Winnock M, Le Bail B, Carles J, Saric J, Balabaud C, BioulacSage P: Increased incidence of HFE C282Y mutations in patients with iron overload and hepato cellular carcinoma developed in noncir rhotic liver. J Hepatol 2000; 32: 805811.
111. Burke W, Imperatore G, McDonnell SM,Baron RC, Khoury MJ: Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Gen Med 2000; 2:271277.
112. ElSerag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology 2007;132: 25572576.
113. Fargion S, Stazi MA, Fracanzani AL, Mattioli M, Sampietro M, Tavazzi D, Bertelli C,Patriarca V, Mariani C, Fiorelli G: Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellu lar carcinoma. Blood Cells Mol Dis 2001;27:505511.
114. Hellerbrand C, Poppl A, Hartmann A,Scholmerich J, Lock G: HFE C282Y hetero zygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 2003;1:279284.
115. Boige V, Castera L, De Roux N, GanneCarrie N, Ducot B, Pelletier G, Beaugrand M,Buffet C: Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 200352: 11781181.
116. Lauret E, Rodriguez M, Gonzalez S, Linares A, LopezVazquez A, MartinezBorra J, Rodrigo L, LopezLarrea C: HFE gene mutations in alcoholic and virusrelated cirrhot ic patients with hepatocellular carcinoma. Am J Gastroenterol 2002;97:10161021.
117. Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, Schischmanoff P, Vidaud D, Charnaux N, Couvert P, GanneCarrie N, Trinchet J, Gattegno L, Beaugrand M: Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008; 134:102110.
118. 1antitrypsin deficiency. Clin Liver Dis 1998 2:175185.
119. 1antitrypsin deficiency: a review. Am J Gastroenterol 2008;103:21362141.
120. 1antitrypsin deficiency. Dig Dis Sci 1987;32:13581362.
121. 1antitrypsin deficiency. Clin Gastroenterol Hepatol 2005; 3: 390396.
122. 1Antitryp sin deficiency: a new paradigm for hepato cellular carcinoma in genetic liver disease. Hepatology 2005;42:514521.
123. 1antitrypsin deficiency as a cofactor in the development of chronic liver disease. Neth J Med 2007; 65: 160166.
124. Kuper H, Tzonou A, Lagiou P, Mucci LA, Trichopoulos D, Stuver SO, Trichopoulou A: Diet and hepatocellular carcinoma: a casecontrol study in Greece. Nutr Cancer 2000;38: 612.
125. Polesel J, Talamini R, Montella M, Maso LD, Crovatto M, Parpinel M, Izzo F, Tom masi LG, Serraino D, Vecchia CL, Frances chi S: Nutrients intake and the risk of hepa tocellular carcinoma in Italy. Eur J Cancer 2007;43:23812387.
126. Talamini R, Polesel J, Montella M, Dal Maso L, Crispo A, Tommasi LG, Izzo F, Crovatto M, La Vecchia C, Franceschi S: Food groups and risk of hepatocellular carcinoma: a multicenter casecontrol study in Italy. Int J Cancer 2006;119:29162921.
127. KuroiwaTrzmielina J, de Conti A, Scolas tici C, Pereira D, Horst MA, Purgatto E, Ong TP, Moreno FS: Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tribu tyrin, a butyric acid prodrug. Int J Cancer 2009;124: 25202527.
128. Chao JCJ, Chu CC: Effects of Ginkgo biloba extract on cell proliferation and cytotoxic ity in human hepatocellular carcinoma cells. World J Gastroenterol 2004; 10:37-41.
129. Cadden ISH, Partovi N, Yoshida EM: Possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol her 2007; 26: 17.
130. Bravi F, Bosetti C, Tavani A, Bagnardi V, allus S, Negri E, Franceschi S, La Vecchia: Coffee drinking and hepatocellular carcinoma risk: a metaanalysis. Hepatology2007; 46:430435.
131. Klatsky AL, Morton C, Udaltsova N, Friedman GD: Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:11901195.
132. Tanaka K, Tokunaga S, Kono S, Tokudome S, Akamatsu T, Moriyama T, Zakouji H:Coffee consumption and decreased serum 7glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998;27:438443.
133. Ruhl CE, Everhart JE: Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928-1936.
134. Larsson SC, Wolk A: Coffee consumption and risk of liver cancer: a metaanalysis. Gastroenterology 2007;132:17401745.
135. Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, Qin LX, Turlin B, Tang ZY, Mazzaferro V, Dejean A: Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res Genet Toxicol Environ Mutagen 2008; 653: 613.
136. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM: Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomark ers Prev 2009; 18: 846853.
137. Chu CH, Kleiner J, Axiotis CA, Di Bisceglie A, Nomura AMY, Stemmermann GN, Tabor E: Mutations of p53 gene in hepatocel lular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. JNatl Cancer Inst 1992;84:16381641.
138. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM: Urinary 15F2tisoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis 2008; 29: 971976.
139. Donato F, Tagger A, Gelatti V, et al: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis infections in men and women. Am J Epidemiol 2002;155:323331.